Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.

Prostate cancer is the most commonly diagnosed cancer disease in men in the Unites States and its management remains a challenge in everyday oncology practice. Thus, advanced therapeutic strategies are required to treat prostate cancer patients. Curcumin (CUR) is a promising anticancer agent for various cancer types. The objective of this study was to evaluate therapeutic potential of novel poly(lactic-co-glycolic acid)- CUR nanoparticles (PLGA-CUR NPs) for prostate cancer treatment. Our results indicate that PLGA-CUR NPs efficiently internalize in prostate cancer cells and release biologically active CUR in cytosolic compartment of cells for effective therapeutic activity. Cell proliferation (MTS), clonogenic, and Western blot analyses reveal that PLGA-CUR NPs can effectively inhibit proliferation and colony formation ability of prostate cancer cells than free CUR. PLGA-CUR NPs showed superior tumor regression compared to CUR in xenograft mice. Further investigations reveal that PLGA-CUR NPs inhibit nuclear β-catenin and AR expression in cells and in tumor xenograft tissues. It also suppresses STAT3 and AKT phosphorylation and leads to apoptosis via inhibition of key anti-apoptotic proteins, Mcl-1, Bcl-xL and caused induction of PARP cleavage. Additionally, significant downregulation of oncogenic miR21 and up-regulation of miR-205 was observed with PLGA-CUR NPs treatment as determined by RT-PCR and in situ hybridization analyses. A superior anti-cancer potential was attained with PSMA antibody conjugated PLGA-CUR NPs in prostate cancer cells and a significant tumor targeting of (131)I labeled PSMA antibody was achieved with PLGA-CUR NPs in prostate cancer xenograft mice model. In conclusion, PLGA-CUR NPs can significantly accumulate and exhibit superior anticancer activity in prostate cancer.

[1]  M. Gianino,et al.  A comparative costs analysis of brachytherapy and Radical Retropubic Prostatectomy therapies for clinically localized prostate cancer , 2009, International Journal of Technology Assessment in Health Care.

[2]  Gang Wang,et al.  Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. , 2008, Cancer research.

[3]  Ilaria Rivolta,et al.  The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions? , 2012, Nanotechnology, science and applications.

[4]  Murali M. Yallapu,et al.  Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes , 2011, International journal of nanomedicine.

[5]  Serge Eifes,et al.  Chemopreventive potential of curcumin in prostate cancer , 2010, Genes & Nutrition.

[6]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[7]  M. Daidone,et al.  miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. , 2009, Cancer research.

[8]  M. Jaggi,et al.  Design of curcumin loaded cellulose nanoparticles for prostate cancer. , 2012, Current drug metabolism.

[9]  B. Conley,et al.  Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.

[10]  B. Aggarwal,et al.  Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. , 2008, Cancer letters.

[11]  Xianfeng Huang,et al.  Curcumin and its formulations: potential anti-cancer agents. , 2012, Anti-cancer agents in medicinal chemistry.

[12]  Xiaoyan Xiao,et al.  Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. , 2012, International journal of pharmaceutics.

[13]  B. Aggarwal,et al.  Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways , 2007, Molecular Pharmacology.

[14]  Thommey P. Thomas,et al.  Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. , 2009, Biomacromolecules.

[15]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Craig C Earle,et al.  How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer? , 2010, Cancer.

[17]  Kirsten Sandvig,et al.  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies , 2011 .

[18]  S. Jain,et al.  A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. , 2011, European journal of pharmacology.

[19]  B. Leiby,et al.  Stat3 promotes metastatic progression of prostate cancer. , 2008, The American journal of pathology.

[20]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[21]  G. Morgia,et al.  Polyphenols: Key Issues Involved in Chemoprevention of Prostate Cancer , 2012, Oxidative medicine and cellular longevity.

[22]  Pingfu Fu,et al.  Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion , 2007, International journal of cancer.

[23]  A. Abbruzzese,et al.  Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[24]  Shadi F Othman,et al.  Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications , 2012, International journal of nanomedicine.

[25]  M. Gleave,et al.  Therapeutic options in advanced prostate cancer: Present and future , 2007, Current urology reports.

[26]  J. Waxman,et al.  Wnt/β-catenin signalling in prostate cancer , 2012, Nature Reviews Urology.

[27]  M. Jaggi,et al.  Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. , 2008, Biochemical and biophysical research communications.

[28]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[29]  R. Agarwal,et al.  Mechanisms of action of novel agents for prostate cancer chemoprevention. , 2006, Endocrine-related cancer.

[30]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[31]  J. Salvador,et al.  The dark side of curcumin , 2010, International journal of cancer.

[32]  Murali M. Yallapu,et al.  Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. , 2010, Journal of colloid and interface science.

[33]  R. Sinha,et al.  Cancer risk and diet in India. , 2003, Journal of postgraduate medicine.

[34]  G. Bar-Sela,et al.  Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer , 2010, Nutrition and cancer.

[35]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[36]  Vasudha Sundram,et al.  Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth , 2010, Journal of ovarian research.

[37]  V. Allan,et al.  Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells , 2005, Journal of Cell Science.

[38]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[39]  H. Aburatani,et al.  Expression and functions of transmembrane mucin MUC13 in ovarian cancer. , 2009, Cancer research.

[40]  F. Aqil,et al.  Advanced Drug Delivery Systems of Curcumin for Cancer Chemoprevention , 2011, Cancer Prevention Research.

[41]  R. Brand,et al.  Chemoprevention strategies for pancreatic cancer , 2010, Nature Reviews Gastroenterology &Hepatology.

[42]  Vasudha Sundram,et al.  Curcumin Attenuates β-catenin Signaling in Prostate Cancer Cells through Activation of Protein Kinase D1 , 2012, PloS one.

[43]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[44]  M. Jaggi,et al.  Bryostatin 1 modulates β-catenin subcellular localization and transcription activity through protein kinase D1 activation , 2008, Molecular Cancer Therapeutics.

[45]  B. Aggarwal.  Prostate cancer and curcumin: Add spice to your life , 2008, Cancer biology & therapy.

[46]  B. Aggarwal,et al.  Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively? , 2009, The AAPS Journal.

[47]  M. Saif,et al.  Desmoplasia in Pancreatic Cancer. Can We Fight It? , 2012, Gastroenterology research and practice.

[48]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[49]  Murali M. Yallapu,et al.  Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. , 2011, Biomaterials.

[50]  L. Rybak,et al.  Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway , 2012, PloS one.

[51]  B. Aggarwal,et al.  Curcumin and cancer: an "old-age" disease with an "age-old" solution. , 2008, Cancer letters.

[52]  E. Gelmann,et al.  Interaction of β-Catenin and TIF2/GRIP1 in Transcriptional Activation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[53]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[54]  Mei Yang,et al.  Lysosomal membrane destabilization induced by high accumulation of single-walled carbon nanohorns in murine macrophage RAW 264.7. , 2012, Biomaterials.

[55]  S. Terry,et al.  Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells , 2006, Oncogene.